噬血细胞性淋巴组织细胞增多症的病因与治疗:是否应更新方案并采用靶向治疗?
该单中心回顾性研究纳入29例成人HLH患者,分析病因、治疗与结局。结果显示靶向治疗组93%(13/14)HLH缓解,而HLH-2004方案组73%(11/15)死亡;风湿免疫病患者对靶向治疗反应良好,对HLH-2004方案反应不佳。
要点
- 靶向治疗组93%(13/14)HLH缓解,仅1例死亡。
- HLH-2004方案组73%(11/15)死亡,仅20%(3/15)缓解。
- 风湿免疫病患者对靶向治疗反应良好,对HLH-2004方案反应不佳。
核心结论
- 风湿免疫病患者对靶向治疗反应良好,对HLH-2004方案反应不佳。
- HLH-2004方案不良结局是否源于方案本身或恶性肿瘤相关HLH的侵袭性尚不明确。
- 需进一步研究制定个体化治疗方案。
研究设计与样本
- 单中心回顾性病历审查,纳入2013至2019年Ochsner Medical Center-New Orleans的29例成人HLH患者。
- HLH诊断依据HLH-2004标准或H-score标准。
主要发现
- 29例中7例有潜在恶性肿瘤,12例有自身免疫病,2例为移植患者,2例为恶性肿瘤、自身免疫病或免疫缺陷的组合,6例由感染单独诱发HLH。
- 所有29例均发热;28例(97%)符合H-score标准,仅20例(67%)符合HLH-2004标准。
- 15例接受HLH-2004方案治疗,其中73%(11/15)死亡,8%(1/15)HLH复发,20%(3/15)HLH缓解。
- 14例接受靶向治疗,其中93%(13/14)HLH缓解,1例死亡。
关键数值与推荐
- HLH-2004方案组:73%(11/15)死亡,8%(1/15)复发,20%(3/15)缓解。
- 靶向治疗组:93%(13/14)缓解,1例死亡。
- 靶向治疗包括脉冲激素、托珠单抗、阿那白滞素、IVIG、CSA、利妥昔单抗和/或CYC,并联合抗病毒或抗生素治疗。
临床怎么用
- 对风湿免疫病相关HLH,靶向治疗(如激素、托珠单抗、阿那白滞素、IVIG、CSA、利妥昔单抗和/或CYC联合抗感染)可能优于HLH-2004方案。
- HLH-2004方案在成人HLH中结局较差,选择时需权衡方案本身与恶性肿瘤相关HLH侵袭性的影响。
局限性
- 单中心回顾性研究,样本量小(29例),结果需外部验证。
- HLH-2004方案不良结局与方案本身或恶性肿瘤相关HLH侵袭性的因果关系不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this study was to analyse the features, therapeutic approaches, and outcomes for adult patients with haemophagocytic lymphohistiocytosis (HLH) at a single centre. METHODS: This study was a retrospective chart review of all patients >18 years of age diagnosed with HLH according to HLH-2004 or H-score criteria at Ochsner Medical Center-New Orleans between 2013 and 2019. RESULTS: A total of 29 patients with HLH met inclusion criteria. A total of 7 patients had an underlying malignancy, 12 had an autoimmune disease, 2 were transplant patients, and 2 had a combination of malignancy, autoimmune disease, or immunodeficiency. A total of 6 patients developed HLH precipitated by infection alone. All 29 patients presented with fever. A total of 28 (97%) patients met H-score criteria, and only 20 (67%) met HLH-2004 criteria. Fifteen patients were treated with the HLH-2004 protocol. Of those treated with the HLH-2004 protocol, 73% (11/15) died, 8% (1/15) had recurrence of HLH, and 20% (3/15) had resolution of HLH. A total of 14 patients were treated with targeted therapy. Of those treated with targeted therapy, 93% (13/14) had resolution of HLH and 1 died. Targeted therapy included pulse steroids, tocilizumab, anakinra, IVIG, CSA, rituximab, and/or CYC in addition to antiviral or antibiotic therapy. CONCLUSION: Our findings suggested that the rheumatologic patient population responded well to a targeted therapeutic approach and poorly to the HLH-2004 protocol. Whether the poor outcomes found with the use of the HLH-2004 protocol are secondary to the protocol itself or the aggressive nature of malignancy-associated HLH is unclear. Further studies are needed to develop tailored therapeutic regimens.
引用
- Posas-Mendoza TF, McLeod C, Davis W, et al. Etiologies and management of haemophagocytic lymphohistiocytosis: is it time for an updated protocol and targeted treatments? Rheumatology (Oxford). 2021. PMID: 33313881. doi:10.1093/rheumatology/keaa741
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。